Arjen Kramer | Senior Principal Scientist
Merus
Arjen Kramer studied Chemistry and obtained a Ph.D. in Enzymology & Protein Engineering at Utrecht University in The Netherlands. Arjen then worked for 5 years at biotechnology company Crucell (now Johnson & Johnson) in Leiden, The Netherlands, specializing in phage display selection and characterization of human antibodies for therapeutic applications. Since 2007, Arjen works at Merus in Utrecht, where his main responsibilities include designing and managing projects related to the discovery of multispecific antibodies for the treatment of cancer patients. In this role, he has been involved in the development and application of various technologies, including the MeMo® transgenic mouse platform for the generation of human antibodies.
Appearances:
Festival of Biologics Day 3 @ 12:20
The making of potent and developable Multiclonics® antibodies
Multispecific antibodies offer unique opportunities through the combination of binding arms to different epitopes or antigens. These engineered antibody formats can result in specificities or functions that are unachievable by classic monovalent antibodies. To generate successful drugs, multispecific antibodies need to be safe and active but also developable and manufacturable. This presentation describes our approach to screen through large panels of Multispecifics that meet all these requirements.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events